Nipent (Pentostatin)

Pentostatin is a purine analog that inhibits the enzyme adenosine deaminase. This inhibition leads to a buildup of deoxyadenosine nucleotides inside lymphocytes, disrupting DNA synthesis and causing selective death of malignant B‑cells while sparing most other cell types.

The dosing regimen for Pentostatin is individualized and determined by the prescribing oncologist or hematologist based on the patient’s disease status, body surface area, renal function, and overall health. Specific dose and schedule information should be obtained from the treating physician.

Pentostatin’s pregnancy category is listed as unknown, and animal data suggest potential fetal risk. Consequently, it is generally avoided in pregnant or nursing women. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose.

To request Nipent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The most common alternative in the same therapeutic class is fludarabine, another purine analog. Both agents target lymphoid malignancies, but Pentostatin has a distinct mechanism—adenosine deaminase inhibition—resulting in a different toxicity profile. Choice between them depends on disease characteristics, prior therapy, and individual patient tolerance.

Nipent should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency.

Nipent is supplied as a sterile intravenous solution and is administered by slow infusion into a peripheral or central vein under the supervision of a qualified healthcare professional. Infusion rates and pre‑medication protocols are determined by the treating physician.

The most serious adverse events include severe infections due to profound immunosuppression, pulmonary toxicity such as interstitial pneumonitis, hepatotoxicity leading to liver failure, and rare but life‑threatening anaphylactic reactions. Patients should be monitored closely for signs of infection, respiratory distress, or liver dysfunction.

Pentostatin is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, in those with active severe infections, and in individuals with significant hepatic or renal impairment where dose adjustment is not feasible. Pregnant or breastfeeding women should also avoid its use.